Immusoft logo

Immusoft

immusoft.com

Immusoft develops cell therapies that program patients’ own B cells to produce therapeutic proteins for sustained delivery. Its therapies are intended for people with rare and other diseases with significant unmet need.

Facts

HQ
Seattle
Sectors
Biotechnology Research
Founded
2009
Type
Corporation Seattle business license
Employees
21
Registered name
Immusoft Corp Seattle business license
Stage
Series B
Members see funding amounts.
.
Founders
Matthew Scholz

Is this your organization? Claim it

Recent coverage

Front-page news, podcasts and videos about Immusoft

See all 7

Immusoft and Takeda partner on B‑cell protein therapies for CNS disorders in deal potentially worth over $900M

Seattle cell therapy startup Immusoft struck a collaboration with Takeda to develop B‑cell–based protein therapies for central nervous system disorders in a deal that could be worth over $900 million. Immusoft will get research funding, an undisclosed upfront payment and option/milestone fees, while Takeda can license preclinical programs and advance products to clinic and commercialization.

Immusoft raises $20M Series B to advance ISP gene therapy and push ISP-001 into Phase I/II for MPS I

Seattle biotech Immusoft raised $20 million in a Series B round to advance its immune system programming (ISP) gene therapy platform, aiming to move lead candidate ISP-001 into Phase I/II trials for MPS I and generate initial safety and efficacy data in 2019; ISP uses patients' blood cells modified to secrete therapeutic proteins and has FDA orphan and rare pediatric disease designations. The company credits progress under new CEO Sean Ainsworth, who replaced founder Matthew Scholz as CEO last year (Scholz is now CTO), and says the platform could broadly replace recombinant enzyme replacement therapies.

By Immusoft

See all 7

Immusoft explores scientific, ethical, regulatory, and practical considerations shaping pediatric cell and gene therapy clinical trial design

This article examines the scientific, ethical, regulatory, and practical factors that influence the design of pediatric cell and gene therapy (CGT) clinical trials, highlighting challenges and considerations specific to children. It aims to guide researchers and stakeholders in creating trials that balance safety, efficacy, and ethical responsibilities for pediatric populations.

People

  • Sean Ainsworth
    Sean Ainsworth Executive, Executive Officer, Director, Chief Executive Officer
  • Scott McIvor Executive, Chief Development Officer

Online

Questions about Immusoft

What is Immusoft?

immusoft.com

Who are the people behind Immusoft?

Seattle Flow lists Sean Ainsworth (Executive, Executive Officer, Director, Chief Executive Officer) and Scott McIvor (Executive, Chief Development Officer) at Immusoft.

Who invested in Immusoft, and how much has it raised?

Members of Seattle Flow see Immusoft's funding rounds, amounts and investors on its Funding tab. Joining is free.

Where is Immusoft based?

Immusoft is headquartered in Seattle.

When was Immusoft founded?

Immusoft was founded in 2009.

How many people work at Immusoft?

Immusoft has 21 employees.